ArticleNeurochemical research2025
Evaluation of the Potential Anticonvulsant and Neuroprotective Effects of Ganoderma Lucidum Extract in an Animal Model of Pentylenetetrazol-Induced Seizures.
Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Erythrina caffra extract restores memory, modulates cholinergic dysfunction, neuroinflammation, and attenuates oxidative stress in cadmium-induced alzheimer's disease-like pathology in rats.Molecular biology reports · 2026Article
- Potential neuroprotective and anticonvulsant effects ofFrontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ganoderma lucidum extract (GLE) has neuro-therapeutic and anticonvulsant effects. This study aimed to evaluate the potential neuroprotective and antioxidant effects of ethanolic extract on pentylenetetrazol-induced brain damage in male Wistar rats and to analyze behavioral manifestations in vivo. Seizure latency, duration, and severity were measured in PTZ-treated rats according to the Racine scale; thus, oxidative stress markers, malondialdehyde (MDA), nitric oxide (NO), and catalase catalytic activity were measured by the 2-thiobarbituric acid, Griess reagent, and hydrogen peroxide methods, respectively. PTZ-injured rats showed both shorter seizure latency and longer seizure duration and intense seizure severity. The effects were enhanced by GLE in a dose-dependent manner. In addition, GLE decreased NO levels, increased catalase levels and decreased MDA levels in the hippocampus and the prefrontal cortex in rats treated with PTZ (75 mg/kg; i.p.). GLE conferred anticonvulsant and neuroprotective effects against PTZ-induced brain damage by repressing molecular processes involved in the production of oxidative stress markers.
Indexed as
Identifiers
40900205What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.